Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on May 27th, 2023%
A recent poll shows U.S. adults continue to favor vaccinations against the childhood diseases mumps, measles, and rubella, but show less support for Covid-19 vaccines. . . . → Read More: Infographic – More US Support for Childhood Vaccines Than Covid-19
By Alan, on April 27th, 2023%
Ultra-low quantities of an experimental Covid-19 protein vaccine delivered in synthetic cell components are shown in lab animals to generate strong immune responses. . . . → Read More: Low-Dose Covid-19 Vaccine Generates Strong Immune Response
By Alan, on April 21st, 2023%
A maker of diagnostics for infectious diseases is receiving a $53.7 million contract to develop and validate reliable home molecular tests for Covid-19 and flu infections. . . . → Read More: Biotech Gains $53.7M Infectious Disease Test Award
By Alan, on March 31st, 2023%
A clinical trial shows a microneedle patch device for vaccine delivery applied by participants to their own arms works as well in the skin as when administered by clinicians. . . . → Read More: Self-Applied Patch Shown Feasible for Vaccine Delivery
By Alan, on March 29th, 2023%
Clinical trial results show an experimental drug given as a chewable tablet reduces viral load and symptoms in people with mild to moderate Covid-19 disease. . . . → Read More: Chewable Covid-19 Drug Reduces Viral Load, Symptoms
By Alan, on February 22nd, 2023%
A company offering DNA analysis tests to detect infectious diseases at home and point-of-care is beginning clinical evaluations of its technology. . . . → Read More: Home Infectious Disease Diagnostic Begins Clinical Tests
By Alan, on February 13th, 2023%
An influenza vaccine given as a nasal spray is shown in a clinical trial to reduce the amount of time participants have flu infections, when exposed to the virus. . . . → Read More: Nasal Spray Reduces Flu Duration in Challenge Trial
By Alan, on January 31st, 2023%
Clinical trial findings show a light-activated disinfectant process kills SARS-CoV-2 viruses in the nose causing Covid-19 infections without harming nasal tissue. . . . → Read More: Light-Activated Treatment Kills Covid-19 Nasal Viruses
By Alan, on January 12th, 2023%
An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics. . . . → Read More: CEPI Assessing Advanced RNA Nanoparticle Vaccine
By Alan, on January 3rd, 2023%
Findings from a clinical trial show an anti-inflammatory drug reduces new symptoms among people with Covid-19 infections and keeps them out of the hospital. . . . → Read More: Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|